Alan Saven

8.4k total citations
120 papers, 5.7k citations indexed

About

Alan Saven is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Alan Saven has authored 120 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Genetics, 43 papers in Oncology and 39 papers in Pathology and Forensic Medicine. Recurrent topics in Alan Saven's work include Chronic Lymphocytic Leukemia Research (85 papers), Lymphoma Diagnosis and Treatment (38 papers) and Viral-associated cancers and disorders (29 papers). Alan Saven is often cited by papers focused on Chronic Lymphocytic Leukemia Research (85 papers), Lymphoma Diagnosis and Treatment (38 papers) and Viral-associated cancers and disorders (29 papers). Alan Saven collaborates with scholars based in United States, United Kingdom and Russia. Alan Saven's co-authors include Lawrence D. Piro, Carol Burian, Ernest Beutler, James A. Koziol, Brunhilde Felding‐Habermann, Emilia Fransvea, Andrea Kay, Grant R. Goodman, Darren Sigal and Kelly Bethel and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Alan Saven

116 papers receiving 5.6k citations

Peers

Countries citing papers authored by Alan Saven

Since Specialization

Citations

This map shows the geographic impact of Alan Saven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Saven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Saven more than expected).

Fields of papers citing papers by Alan Saven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Saven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Saven. The network helps show where Alan Saven may publish in the future.

Co-authorship network of co-authors of Alan Saven

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Saven. A scholar is included among the top collaborators of Alan Saven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Saven. Alan Saven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hairy cell leukemia: a ‘hair-raising’ update 2014 ·Expert Review of Hematology ·(unknown), Alan Saven	1
2	Cladribine in indolent non-Hodgkin’s lymphoma 2008 ·Expert Review of Anticancer Therapy ·Darren Sigal, Alan Saven	6
3	Hairy Cell Leukemia 2007 ·PubMed ·Paul T. Fanta, Alan Saven	11
4	Cladribine in Hairy Cell Leukemia 2006 ·Hematology/Oncology Clinics of North America ·Rajesh Belani, Alan Saven	9
5	Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma 2006 ·Cancer ·Kristie A. Blum, Jeffrey L. Johnson, Donna Niedzwiecki, Lawrence D. Piro, Alan Saven, B. A. Peterson, John C. Byrd, Bruce D. Cheson, (unknown)	12
6	Reactive thrombocytosis associated with a pheochromocytoma 2005 ·Thrombosis and Haemostasis ·Lyudmila Bazhenova, Emma Du, Sunil Bhoyrul, James McCallum, Alan Saven	2
7	Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis 2004 ·Proceedings of the National Academy of Sciences ·Brunhilde Felding‐Habermann, Richard A. Lerner, Antonietta M. Lillo, Shufei Zhuang, Martin R. Weber, (unknown), Changshou Gao, Shenlan Mao, Alan Saven, Kim D. Janda	30
8	Cladribine: from the bench to the bedside – focus on hairy cell leukemia 2004 ·Expert Review of Anticancer Therapy ·(unknown), Alan Saven	9
9	CD52 expression in hairy cell leukemia 2003 ·American Journal of Hematology ·Michael Quigley, Kelly Bethel, Robert W. Sharpe, Alan Saven	35
10	Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer 2001 ·British Journal of Cancer ·Robert E. Smith, Ishmael Jaiyesimi, Luís Meza, N. Simon Tchekmedyian, (unknown), (unknown), Stanley A. Brosman, Ronald M. Bukowski, (unknown), Mark U. Rarick, Alan Saven, Alan Colowick, A. Fleishman, Urte Gayko, John A. Glaspy	69
11	An Open-label Pilot Trial of Cladibrine (2-Chlorodeoxyadenosine) in Patients with Primary Sclerosing Cholangitis 2000 ·Journal of Clinical Gastroenterology ·Andrea Duchini, Z.M. Younossi, Alan Saven, Gerald M. Bordin, Helen J. Knowles, (unknown)	28
12	Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma 1999 ·Annals of Oncology ·Lawrence D. Piro, Christine A. White, A.J. Grillo-López, Nalini Janakiraman, Alan Saven, T Beck, C. Varns, Steve Shuey, M. S. Czuczman, James W. Lynch, (unknown), Vinay Jain	308
13	Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia 1998 ·British Journal of Haematology ·Eva S. Liu, Carol Burian, William E. Miller, Alan Saven	53
14	Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. 1997 ·Journal of Clinical Oncology ·BR Meisenberg, William E. Miller, R McMillan, Mary Callaghan, Caroline E. Sloan, (unknown), Michael P. Kosty, Joan F. Kroener, Robert L. Longmire, Alan Saven, Lawrence D. Piro	55
15	Acute Myelogenous Leukemia Presenting with Bulky Lymphadenopathy 1996 ·Acta Haematologica ·Russell Gollard, Bruce A. Robbins, Lawrence D. Piro, Alan Saven	8
16	Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. 1996 ·Journal of Clinical Oncology ·Alan Saven, (unknown), Michael P. Kosty, Lawrence D. Piro	39
17	Complete hematologic remissions in chronic-phase, philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine 1994 ·Cancer ·Alan Saven, Lawrence D. Piro, (unknown), (unknown), Michael P. Kosty, Douglas J. Ellison, Ernest Beutler	24
18	2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. 1993 ·Journal of Clinical Oncology ·Alan Saven, Hajime Kawasaki, (unknown), T A Waltz, Brian R. Copeland, Jack Zyroff, Michael P. Kosty, Dennis A. Carson, Ernest Beutler, Lawrence D. Piro	41
19	2-Chlorodeoxyadenosine treatment of low-grade lymphomas. 1992 ·Journal of Clinical Oncology ·Andrea Kay, Alan Saven, (unknown), Dennis A. Carson, Donald L. Thurston, Ernest Beutler, Lawrence D. Piro	149
20	Morbidity trends in the medical wards at Groote Schuur Hospital--1971 and 1982. 1985 ·PubMed ·S R Benatar, Alan Saven	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact